Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923447 | 0.96 | CYP2C9 (0.34) | LMNASMN1; SMN2CYP2C9POLBMAPT | |
| SCHEMBL2923087 | 0.94 | LMNA (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL2919065 | 0.94 | KMT2A (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL2924051 | 0.94 | CYP2C9 (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL4583145 | 0.94 | CYP2C9 (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL2917088 | 0.94 | CYP2C9 (0.34) | LMNASMN1; SMN2KMT2ACYP2C9TP53 | |
| SCHEMBL2922488 | 0.94 | CYP2C9 (0.34) | LMNASMN1; SMN2KMT2ACYP2C9TP53 | |
| SCHEMBL2923691 | 0.94 | FKBP1A (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL2916770 | 0.94 | FKBP1A (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A | |
| SCHEMBL1036670 | 0.93 | KMT2A (0.35) | LMNASMN1; SMN2KMT2ACYP2C9FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-1015887-B1 | NONINVASIVE TRANSDERMAL SYSTEMS FOR DETECTING ANALYTES | ARONOWITZ JACK L (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100049016-A1 | Noninvasive Transdermal Systems for Detecting an Analyte in a Biological Fluid and Methods | ARONOWITZ JACK L | 2010-02-25 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-7577469-B1 | Noninvasive transdermal systems for detecting an analyte in a biological fluid and methods | Aronowitz, Jack L. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| US-6503198-B1 | Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods | ARONOWITZ, JACK L. | 2003-01-07 | — | — | US | disclosed |
| WO-1994012879-A1 | DRY REAGENT THREE ELEMENT ANALYTE DETECTION SYSTEM | ARONOWITZ JACK L (US) | 1994-06-09 | — | — | WO | disclosed |
| US-4774192-A | A dry reagent delivery system with membrane having porosity gradient | TECHNIMED CORPORATION (US) | 1988-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | LMNA 655/4885SMN1; SMN2 2302/4885KMT2A 2879/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | LMNA 2502/4885SMN1; SMN2 2529/4885KMT2A 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.